Best in Biotech 22 Jan 2024 Eight newly approved drugs that could become blockbusters in 2024 The much-awaited Drugs to Watch list by Clarivate is out. Let’s do a deep dive into the therapies that made the cut in 2024. January 22, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 19 Jan 2024Epigenetic editing – the power of CRISPR without cutting DNA Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […] January 19, 2024 Share WhatsApp Twitter Linkedin Email
Podcast 5 Jan 2024Gene editing in the microbiome could provide acne solution Explore Eligo Bioscience’s groundbreaking CRISPR-based approach, modifying the microbiome to combat moderate to severe acne. January 5, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2023 Wrapping up 2023: A recap of top biotech moments of this year 2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023. December 20, 2023 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […] December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Oct 2023 Saving lives with xenotransplantation: how biotechs are solving the transplant shortage crisis On January 7, 2022, a surgery was performed on David Bennett to give him a new heart. But this was no ordinary transplant surgery. Instead of receiving a heart from a human donor, the 57-year-old, who did not qualify for a traditional transplant, received a pig heart. This surgery marked a historic breakthrough, becoming the […] October 5, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Sep 2023 Base editing hits the clinic in the U.S. Over the past couple of years, base editing, a recent offshoot of the heralded CRISPR/Cas 9 technology, has been doing its rounds in the biotech space. Now, base editing has finally set foot into clinical trials for the first time in the U.S.. American precision medicine company Beam Therapeutics treated its first patient with its […] September 25, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 19 Jul 2023 Genetic engineering giants: is China poised to lead the way? For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […] July 19, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2023 New platform cuts time engineering and selecting genome editors A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […] June 28, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 May 2023 Five advancements in lupus research over the past year A condition that affects around five million people worldwide, lupus has no proven cure. But various treatments for the disease have been around for more than a century, and lupus research has grown over the years. The first kind of therapy for the autoimmune disease – which occurs due to an overactive immune system that […] May 4, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Eterna acquires allogeneic immuno-oncology platform from Exacis Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […] May 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email